Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.

Tavapadon will enter a competitive but commercially attractive market after a likely regulatory submission following post-hoc data.

Results provide evidence needed to challenge the step-through reimbursement requirements that have restricted Qulipta's uptake in Europe.

In April 2026, Biogen announced that it would acquire exclusive rights to TJ Biopharma’s felzartamab in Greater China for up to $850m.

The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.

Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canada-based Apotex for $100m in cash.

OZMOSI and Planview have partnered to link external scientific data with internal R&D planning to support pharmaceutical organisations.

This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.

Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical trials.

UK Biobank data from all 500,000 participants within the charity’s health database was put up for sale on the Chinese e-commerce website Alibaba.

Sanofi has received approval from the US FDA for a supplemental biologic licence application for Tzield, allowing its use to delay stage 3 T1D onset in children as young as one year diagnosed with ...